IgE Autoantibodies: an Innate Connection to Adaptive Immunity
Xin Huang,Mikael C. I. Karlsson
DOI: https://doi.org/10.1016/j.jaci.2021.03.036
2021-01-01
Abstract:The IgE antibody was first discovered in 1919 through the search for the serum factor causing allergic reactions during blood transfers and was subsequently described as a distinct antibody subclass in 1960s.1Johansson S.G. Raised levels of a new immunoglobulin class (IgND) in asthma.Lancet. 1967; 2: 951-953Abstract PubMed Google Scholar IgE is mostly well known for its role in hypersensitivity, parasite infection, and venom neutralization. Systemically, IgE is mostly localized close to mucosal surfaces and can be activated by extremely small amounts of antigen, even through aerosol exposure. It exerts a gatekeeper function in the immune system to activate innate immune cells.2Auge J. Vent J. Agache I. Airaksinen L. Campo Mozo P. Chaker A. et al.EAACI position paper on the standardization of nasal allergen challenges.Allergy. 2018; 73: 1597-1608Crossref PubMed Scopus (106) Google Scholar However, recent studies have revealed that IgE responses are not limited to foreign antigens, as they can also be found in several autoinflammatory diseases and can potentially add to autoimmune responses (Table I).Table IAuto-IgE in autoimmune diseases (examples)DiseaseIgE level (specificity)PatientsRelevance with disease activityMechanismsReferences (digital object identifier)SLENuclear antigen–specific IgE level (32%).1 dsDNA-, SS-A–, SS-B–, Sm-specific IgE level (50%)2/human P2 protein–specific IgE level (31%)392/196/90dsDNA IgE is related to disease activity and low IL-4, IL-5 levels.2 SS-A IgE is connected to pregnancy complications4Activate basophils and promote a TH2 environment with autoantibody production. Activate plasmacytoid DCs, increase IFN-α production1,51. Atta et al. 10.1159/0002882932. Dema et al. 10.1371/journal.pone.00904243. Rhyner et al. 10.1111/j.1398-9995.2011.02581.x4. Sekigawa et al. 10.1080/030097403100046585. Augusto et al.10.1016/j.autrev.2017.11.027Pemphigus vulgarisTotal IgE level (40%),6 Dsg3-specific IgE level (13%),7 Dsg1-specific IgE level (81%)893/41/143∗In patients with pemphigus foliaceus.Dsg3 IgE is strongly correlated with disease activity in patients with acute-onset pemphigus vulgaris6n/a6. Nagel et al. 10.1016/j.clim.2009.11.0067. Spaeth et al. 10.1046/j.1365-2133.2001.04228.x8. Qian et al. 10.1038/jid.2010.403Bullous pemphigoidTotal IgE level (60%), BP180-specific IgE level (10%), BP230-specific IgE level (34%),9 BP180-specific IgE level (40.2%)1050/65BP180 IgE is correlated with the total BPDAI but is not associated with urticarial or erythematous pemphigoid10FcεR1-mediated activation of granulocytes. Decrease of hemidesmosomes, inflammatory cytokine release, and epidermal cell extracellular matrix integrity9. Lamberts et al. 10.1111/jdv.1699610. van Beek et al. 10.1001/jamadermatol.2016.3357Nonbullous pemphigoidTotal IgE level (63%), BP230-specific IgE level (22%), BP180-specific IgE level (9%)968n/aNot studied9. Lamberts et al. 10.1111/jdv.16996Rheumatoid arthritisTotal IgE level,11 specific IgE level (60%)1221/20Related to extraarticular manifestationsType I inflammatory reactions11. Meretey et al. 10.1136/ard.41.4.40512. Permin et al. 10.1111/j.1699-0463.1978.tb02587.xMixed connective diseaseU1-snRNP–specific IgE (80%)1316Related to mixed connective tissue disease-like lung diseaseBasophil accumulation and activation, release of cytokines.13. Lamri et al. 10.1016/j.jaci.2020.12.622Chronic spontaneous urticaria>200 types of antigen-specific IgE, including IL-24–specific IgE (80%)141062IL-24 IgE correlated with chronic spontaneous urticaria disease activityFceR1-dependent degranulation of mast cells and basophils1514. Schmetser et al. 10.1016/j.jaci.2017.10.03515. Hatada et al. 10.1159/000350388Multiple sclerosisTotal IgE level (69%)1626n/an/a16. Mikol et al. 10.1016/j.jneuroim.2006.06.030BPDAI, Bullous Pemphigoid Disease Activity Index; dsDNA, double-stranded DNA; n/a, not available.∗ In patients with pemphigus foliaceus. Open table in a new tab BPDAI, Bullous Pemphigoid Disease Activity Index; dsDNA, double-stranded DNA; n/a, not available. B cells producing IgE antibodies are generated through class switch recombination (CSR), coupling the Cε heavy chain to the prearranged VDJ antigen-binding domain. The antibody gene is subsequently enhanced for antigen binding through somatic hypermutation. Both processes are mediated by the enzyme activation-induced deaminase (AID) and coupled with the germinal center (GC) reaction. Class switching is an early event that happens in the early GC reaction or even before its generation.3Roco J.A. Mesin L. Binder S.C. Nefzger C. Gonzalez-Figueroa P. Canete P.F. et al.Class-switch recombination occurs infrequently in germinal centers.Immunity. 2019; 51: 337-350.e7Abstract Full Text Full Text PDF PubMed Scopus (139) Google Scholar In the case of IgE, switching can occur either directly from the constant regions Cμ/Cδ expressed by naive B cells or in a sequential manner through IgG1 (Cγ1).4Ramadani F. Bowen H. Upton N. Hobson P.S. Chan Y.C. Chen J.B. et al.Ontogeny of human IgE-expressing B cells and plasma cells.Allergy. 2017; 72: 66-76Crossref PubMed Scopus (31) Google Scholar It is likely that the sequential IgE switch occurs through the reactivation of IgG1-positive memory cells that have already gone through affinity maturation. Alternatively, switching to IgE can also occur during extrafollicular B cell responses. This typically generates low-affinity responses due to the absence of somatic hypermutation. Compared with the other immunoglobulin subclasses, IgE is found in only trace amounts and has a much shorter half-life (12 hours) than does IgG, which can stay in circulation for up to 8 days in mice.5Vieira P. Rajewsky K. The half-lives of serum immunoglobulins in adult mice.Eur J Immunol. 1988; 18: 313-316Crossref PubMed Scopus (320) Google Scholar IgE antibodies have the capacity to bind 2 distinct Fc receptors, namely, the high-affinity receptor FcεRI and the low-affinity receptor FcεRII (CD23). These 2 receptors belong to different receptor families, with FcεRI containing antibody domains and CD23 being a C-type lectin. FcεRI is expressed on granulocyte, monocyte, and dendritic cell (DC) subpopulations. In contrast, the CD23 receptor is expressed by B cells and follicular DCs, and it can be upregulated on macrophages, DCs, and eosinophils. The binding of IgE to Fc receptors is influenced by glycosylation. It has been shown that a specific N-linked sialic acid in the constant domain 3 is necessary for binding to FcεRI. The glycosylation patterns with increased sialic acid coupled with IgE are correlated with inflammatory disease and the removal of sialic acid, reduced anaphylactic responses.6Shade K.C. Conroy M.E. Washburn N. Kitaoka M. Huynh D.J. Laprise E. et al.Sialylation of immunoglobulin E is a determinant of allergic pathogenicity.Nature. 2020; 582: 265-270Crossref PubMed Scopus (42) Google Scholar B-cell activation and the switch to IgE require CD40-mediated costimulation and extra signals from T cells, especially CD4+ TH2 cells and follicular T helper cells (TFH) cells. Among the cytokines, IL-4/IL-13 is the most important inducer of IgE CSR. Other cytokines such as IFN-γ, TGF-β, and IL-2 counteract this response. The downstream signals of IL-4/IL-13 receptor activation in B cells are connected to a network of transcription factors such as AID, which is needed for basic CSR, and factors steering toward IgE, including signal transducer and activator of transcription 6 (STAT6) and NFIL-3 (Fig 1). A recent study showed that a novel subset called TFH13 cells (producing IL-4, IL-5, IL-13, and reduced amounts of IL-21) is critical for high-affinity IgG1 and IgE.7Gowthaman U. Chen J.S. Zhang B. Flynn W.F. Lu Y. Song W. et al.Identification of a T follicular helper cell subset that drives anaphylactic IgE.Science. 2019; 365Crossref PubMed Scopus (137) Google Scholar The source for IL-4 driving IgE switch has been shown to be Bcl6+ TFH cells rather than GATA3hi TH2 cells. This might be partly explained by the fact that TH2 cells primarily reside in peripheral tissues rather than in secondary lymphoid organs. IL-21 is also important, as IgE switch has been shown to be more potent when there is a lower IL-21 level. The TFH cell–driven activation of B cells is counteracted by regulatory T (Treg) cell subsets. The subsets of Treg cells also include the recently described follicular Treg cells (Tfr cells), which develop from thymic precursors with a suppressive function toward TFH cells and B-cell activation, and specifically, class switch to IgE. Deletion of Tfr cells in mouse models also increases activation of TFH13 cells, resulting in increased levels of self-reactive IgG and IgE (Fig 1). Nonconventional T cells are also involved in regulating IgE antibody responses. Of these, the most studied are invariant NKT (iNKT) cells. In the glycolipid-driven B-cell response, iNKT cells become iNKTFH cells, which are similar to TFH cells with regard to capacity for costimulation and migratory patterns. In IgE responses and autoimmunity, iNKT cells impose negative regulation supported by B-helper neutrophils (NBHs). In a model system using IL-18 to induce autoinflammation, NBHs migrate to the spleen to induce B-cell activation and IgE production. This response was negatively regulated by iNKT cells that get activated and polarized by neutrophils.8Enoksson S.L. Grasset E.K. Hagglof T. Mattsson N. Kaiser Y. Gabrielsson S. et al.The inflammatory cytokine IL-18 induces self-reactive innate antibody responses regulated by natural killer T cells.Proc Natl Acad Sci U S A. 2011; 108: E1399-E1407Crossref PubMed Scopus (47) Google Scholar iNKT cells induced killing through FAS-mediated mechanisms preventing B cells from producing autoreactive IgE antibodies. When glycolipid is injected together with IL-18, NKT cells change polarization to become iNKTFH cells. These iNKTFH cells then support the response instead, also increasing autoimmunity in a model of rheumatoid arthritis. Further studies of the IL-18– and NBH-driven IgE response are needed to see whether it is connected to TFH13-driven IgE responses. One hypothesis is that because the response is very quick and extrafollicular, the IL-18–induced IgE switch does not occur via IgG1 (Fig 1). Also, IL-18 induces a cytokine profile dominated by IFN-γ production, suggesting that the response is initiated and regulated differently. The potentially different pathways to IgE production likely contribute to the addition of IgE memory in different ways. This could be connected to memory generation, as it was shown in mice (by using transfer of IgG1 and IgE B cells with the GC phenotype) that only the IgG1 cells give rise to memory. This would suggest that sequential switching and the GC response are more important for IgE memory. In addition, neutrophils have been suggested to be the source of autoantigens through neutrophil extracellular traps (NET) formation, but whether this connects directly to auto-IgE responses has not been determined. The lack of iNKT cells is also connected to auto-IgE in inflammatory diseases. Reduced numbers of iNKT cells are found in humans with hyper-IgE syndrome, which is a disease caused by STAT3 gene mutations. The decrease in iNKT cells is related to highly inflammatory cytokines, including IL-18, that reprogram iNKT cells. In patients with atopic eczema, IL-18 level is increased in serum and is correlated with the IgE level of patients with atopic eczema and dysregulated iNKT cells. iNKT cells producing IFN-γ and IL-4 are also part of the cellular infiltrate in the skin lesions of atopic eczema together with B cells.9Lind S.M. Kuylenstierna C. Moll M. E DJ Winqvist O. Lundeberg L. et al.IL-18 skews the invariant NKT-cell population via autoreactive activation in atopic eczema.Eur J Immunol. 2009; 39: 2293-2301Crossref PubMed Scopus (30) Google Scholar To measure IgE level, switch circles in situ can be determined by detecting the tissue DNA that is excised after CSR. By using this method, the authors of a study of systemic sclerosis demonstrated that direct and sequential switching had occurred in B cells found in the skin. Clinically, increased levels of self-reactive IgE antibodies in serum have been found in many autoimmune diseases, including SLE, autoimmune bullous diseases, chronic spontaneous urticaria, mixed connective tissue disease, rheumatoid arthritis, and others (Table I). However, the presence of IgE is not correlated with atopy because the frequency of allergy, including asthma and eczema, was not higher in patients with an autoimmune disorder. This suggests that the mechanisms of action are connected to specificity, and indeed, several studies have shown a strong connection between specific autoreactive IgE and disease activity. One possible pathway for IgE-driven pathology is through type 1 interferons that are produced by self-reactive immune complexes that activate plasmacytoid DCs. The anti-DNA IgE antibodies can increase Toll-like receptor 9 activation in pDCs through binding to FcεRI, leading to the increased production of IFN-γ. This is evidenced by Lyn-deficient lupus-prone mice, in which IgE activates basophils to promote inflammation in connection with glomerulonephritis. With regard to disease etiology, it has been shown that polymorphisms of the LYN gene are associated with SLE disease. In addition, a protective effect of total nonautoreactive IgE has been suggested through inhibition of the secretion of IFN-α by FcεRI-triggered plasmacytoid DCs.10Augusto J.F. Truchetet M.E. Charles N. Blanco P. Richez C. IgE in lupus pathogenesis: Friends or foes?.Autoimmun Rev. 2018; 17: 361-365Crossref PubMed Scopus (14) Google Scholar The clinical relevance of specifically targeting IgE and the B cells that produce it for treatment of autoimmune disease remains to be determined. Anti-IgE therapy for atopic dermatitis has given varied results, and despite reductions of serum IgE level and decreased FcεRI expression on granulocytes, it was determined that such therapy provides little improvement of clinical symptoms. It has also been shown that omalizumab could alleviate the disease activity of SLE and bullous pemphigoid. It may be that part of the inflammatory mechanisms are IgE independent and that targeting this molecule specifically is not enough. On the other hand, the tolerance mechanisms that have been broken to give autoimmunity, including IgE production, are likely broader, and the detection of auto-IgE here could be an indicator of treatment efficacy or disease activity. Also, the development of treatments targeting glycosylation patterns of antibodies to modulate Fc receptor binding could give new avenues for treatment. We thank Malin Winerdal for illustrations.